Socio-behaviour challenges to phase III HIV vaccine trials in Sub-Saharan Africa
- PMID: 16245989
- PMCID: PMC1831933
- DOI: 10.5555/afhs.2005.5.3.198
Socio-behaviour challenges to phase III HIV vaccine trials in Sub-Saharan Africa
Abstract
Background: A number of countries in sub-Saharan Africa are preparing for HIV vaccine efficacy trials. Social and behavioural factors related to HIV transmission require examination in each setting where these trials are considered. As part of this, several countries have also recently begun preparatory research investigating relevant social and behavioural issues. There is a need for a review of the literature to help focus such research efforts in Sub-Saharan Africa.
Objectives: To examine key social and behavioural issues that may impact on the conduct of HIV vaccine efficacy trials in sub-Saharan Africa.
Design: Literature review
Methods: Major databases (PubMed, PsychInfo, EBSCOhost, and AIDSline) were searched for literature that discussed social and behavioural issues related to HIV vaccine trials. Three areas are highlighted as being particularly significant for HIV vaccine research: (1) willingness to participate in future HIV vaccine efficacy trials, (2) retention of participants in studies, and (3) sexual risk reporting during trials. For each of these topics, major findings from both developed and developing countries are described and avenues for further research are discussed.
Results: There are few data from Sub-Saharan Africa regarding willingness to participate in HIV vaccine trials. Data on participant retention rates varies widely, and maintaining large cohorts of individuals within Phase III trials presents an important challenge. In addition, the possible impact of trial participation on sexual disinhibition, and response bias on sexual risk-reporting remain as issues for HIV vaccine trials in African contexts.
Conclusion: Social and behavioural research forms an important part of preparations for HIV vaccine efficacy trials, and there is a clear need for more research of this type in Sub-Saharan Africa. Innovative approaches are required to address issues such as willingness to participate in vaccine research, participant retention during efficacy trials, and the accurate reporting by participants of sexual risk behaviours.
Similar articles
-
Willingness to participate in HIV vaccine efficacy trials among high risk men and women from fishing communities along Lake Victoria in Uganda.Vaccine. 2013 Oct 17;31(44):5055-61. doi: 10.1016/j.vaccine.2013.08.080. Epub 2013 Sep 7. Vaccine. 2013. PMID: 24021306 Free PMC article.
-
Future access to HIV vaccines. Report from a WHO-UNAIDS Consultation, Geneva, 2-3 October 2000.AIDS. 2001 May 4;15(7):W27-44. AIDS. 2001. PMID: 11399975
-
Participants' characteristics and motivations to screen for HIV vaccine and monoclonal antibody trials in KwaZulu-Natal, South Africa.Trials. 2021 Dec 11;22(1):897. doi: 10.1186/s13063-021-05792-7. Trials. 2021. PMID: 34895272 Free PMC article.
-
Contemporary issues on the epidemiology and antiretroviral adherence of HIV-infected adolescents in sub-Saharan Africa: a narrative review.J Int AIDS Soc. 2015 Sep 16;18(1):20049. doi: 10.7448/IAS.18.1.20049. eCollection 2015. J Int AIDS Soc. 2015. PMID: 26385853 Free PMC article. Review.
-
[Current status of the female condom in Africa].Sante. 1997 Nov-Dec;7(6):405-15. Sante. 1997. PMID: 9503499 Review. French.
Cited by
-
Feasibility and acceptability of using biometric fingerprinting to track migrations and support retention in HIV prevention research in fishing population in East Africa.BMC Public Health. 2023 Dec 1;23(1):2383. doi: 10.1186/s12889-023-17339-3. BMC Public Health. 2023. PMID: 38041047 Free PMC article.
-
Conceptual framework for behavioral and social science in HIV vaccine clinical research.Vaccine. 2011 Oct 13;29(44):7794-800. doi: 10.1016/j.vaccine.2011.07.108. Epub 2011 Aug 5. Vaccine. 2011. PMID: 21821083 Free PMC article.
-
Advances in HIV Treatment and Vaccine Development: Emerging Therapies and Breakthrough Strategies for Long-Term Control.AIDS Res Treat. 2025 Jul 4;2025:6829446. doi: 10.1155/arat/6829446. eCollection 2025. AIDS Res Treat. 2025. PMID: 40655875 Free PMC article. Review.
-
An assessment of fishing communities around Lake Victoria, Uganda, as potential populations for future HIV vaccine efficacy studies: an observational cohort study.BMC Public Health. 2014 Sep 22;14:986. doi: 10.1186/1471-2458-14-986. BMC Public Health. 2014. PMID: 25242015 Free PMC article.
-
What motivates or demotivates injecting drug users to participate in hypothetical HIV vaccine efficacy trials? A qualitative study from urban Tanzania.East Afr Health Res J. 2020;4(2):128-139. doi: 10.24248/eahrj.v4i2.636. Epub 2020 Nov 26. East Afr Health Res J. 2020. PMID: 34308230 Free PMC article.
References
-
- Esparza J, Bhamarapravati N. Accelerating the development and future availability of HIV-1 vaccines: why, when, where, and how? Lancet. 2000;355:2061–2066. - PubMed
-
- UNAIDS, author. Fourth global report on the AIDS epidemic. Geneva, Switzerland: UNAIDS; 2004.
-
- Myer L, Morroni C, Susser ES. The social pathology of the HIV/AIDS pandemic. Int J Epidemiol. 2003;32:189–192. - PubMed
-
- Dunkle KL, Jewkes RK, Brown HC, Gray GE, McIntyre JA, Harlow SD. Gender-based violence, relationship power, and risk of HIV infection in women attending antenatal clinics in South Africa. Lancet. 2004;363:1415–1421. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials